Ankyrin Repeat Domain 1, <i>ANKRD1</i>, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer
Lyndee L. Scurr(The University of Sydney), Anna DeFazio(The University of Sydney), Gerard Wain(Westmead Hospital), Catherine J. Kennedy(The University of Sydney), Karen Byth(Westmead Hospital), Helen Rizos(Macquarie University), Paul R. Harnett(The University of Sydney), Alison H. Brand(The University of Sydney), Rosemary L. Balleine(The University of Sydney), Raghwa Sharma(Royal Prince Alfred Hospital), Ying Lei(Xi'an University of Science and Technology), Alexander Guminski(The University of Sydney), Yoke-Eng Chiew(Millennium Institute), Kylie Pryor(The University of Sydney)
Cited by 44
Related Papers
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Driver mutations in <i>TP53</i> are ubiquitous in high grade serous carcinoma of the ovary
|The Journal of Pathology|2010|836